Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Idarubicin: an anthracycline antineoplastic agent.

R J Cersosimo1

  • 1College of Pharmacy and Allied Health Professions, Northeastern University, Boston, MA 02115.

Clinical Pharmacy
|February 1, 1992
PubMed
Summary

Idarubicin, a daunorubicin analogue, is effective for acute nonlymphocytic leukemia and shows promise for other cancers. It offers oral bioavailability and potentially less cardiotoxicity compared to other anthracyclines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Irinotecan: a new antineoplastic agent for the management of colorectal cancer.

The Annals of pharmacotherapy·1999
Same author

Topotecan: a new topoisomerase I inhibiting antineoplastic agent.

The Annals of pharmacotherapy·1999
Same author

Hiccups with high dose dexamethasone administration: a case report.

Cancer·1998
Same author

Creatine kinase elevation associated with 5-fluorouracil and levamisole therapy for carcinoma of the colon. A case report.

Cancer·1996
Same author

Prostate cancer: current and evolving strategies.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1996
Same author

Hepatotoxicity associated with cisplatin chemotherapy.

The Annals of pharmacotherapy·1993

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Idarubicin is an anthracycline antibiotic used in cancer chemotherapy.
  • It is a structural analogue of daunorubicin.

Purpose of the Study:

  • To review the mechanism of action, pharmacokinetics, activity, adverse effects, and administration of idarubicin.
  • To compare idarubicin's efficacy and safety with other anthracyclines.

Main Methods:

  • Review of existing literature on idarubicin.
  • Analysis of clinical trial data comparing idarubicin-based regimens with daunorubicin-based regimens.

Main Results:

  • Idarubicin is approved for adult acute nonlymphocytic leukemia (ANLL) and is at least as effective as daunorubicin.
  • Idarubicin-cytarabine regimens show greater activity and longer survival than daunorubicin-cytarabine regimens in ANLL.
  • Idarubicin demonstrates activity in acute lymphocytic leukemia, lymphomas, and breast cancer.
  • Adverse effects are similar to other anthracyclines, with potentially less cardiotoxicity.
  • Idarubicin has significant oral bioavailability (28%), with an oral dosage form under investigation.

Conclusions:

  • Idarubicin is an effective agent for ANLL management.
  • It is potentially more potent and less cardiotoxic than daunorubicin or doxorubicin.
  • Further research is needed to define the maximum cumulative dose to prevent cardiotoxicity.

Related Experiment Videos